Repetitive transcranial magnetic stimulation helped reduce cannabis use by up to 60% in those with schizophrenia who have cannabis use disorder.
People diagnosed with mental health disorders are more likely to report poor sleep quality, including sleep disturbances and problems falling back to sleep, than the general population.
While cannabis users reported more psychotic experiences than non-users generally, the effect was more pronounced in those with a genetic risk factor for schizophrenia.
Suicide rates for those with schizophrenia spectrum disorders (SSD) are 170 times higher than the general population. Suicide risk is predicted by key factors including age, evidence of mood disorders and hospitalization. An increased risk of suicidal behavior in those with SSD occurrs within the first five years following diagnosis.
Study demonstrates a molecular mechanism that contributes to the development of PTSD. The findings could lead to therapeutic interventions for preventing or treating the disorder.
Researchers have developed new therapeutic molecules that appear to assist in reversing memory loss associated with depression and aging.
A new study reports sub-groups of people use their brains differently when imitating emotional faces. For those with schizophrenia, researchers found no categorically different social brain functions than those without the condition, but do fall into different sub-groups that respond to different types of treatments.
Amiloride, a common blood pressure medication, shows potential in treating anxiety disorder and pain when administered in nebulized form, researchers report.
A new study reveals people with schizophrenia have a disrupted stress response. Researchers report those with schizophrenia have an increase in dopamine release in the striatum, but not in the prefrontal cortex, in response to stress.
According to researchers, 40% of people with treatment resistant depression who received rTMS no longer had suicidal thoughts following treatment.